Ten things you should know about protein kinases: IUPHAR Review 14

被引:249
作者
Fabbro, Doriano [1 ]
Cowan-Jacob, Sandra W. [2 ]
Moebitz, Henrik [2 ]
机构
[1] PIQUR Therapeut, CH-4057 Basel, Switzerland
[2] Novartis Inst Biomed Res, Basel, Switzerland
基金
英国惠康基金;
关键词
CHRONIC MYELOID-LEUKEMIA; CELL LUNG-CANCER; TYROSINE KINASE; SMALL-MOLECULE; BCR-ABL; ACQUIRED-RESISTANCE; SELECTIVE INHIBITOR; IRREVERSIBLE INHIBITORS; TARGETING KINASES; MAP KINASE;
D O I
10.1111/bph.13096
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Many human malignancies are associated with aberrant regulation of protein or lipid kinases due to mutations, chromosomal rearrangements and/or gene amplification. Protein and lipid kinases represent an important target class for treating human disorders. This review focus on the 10 things you should know about protein kinases and their inhibitors', including a short introduction on the history of protein kinases and their inhibitors and ending with a perspective on kinase drug discovery. Although the 10 things' have been, to a certain extent, chosen arbitrarily, they cover in a comprehensive way the past and present efforts in kinase drug discovery and summarize the status quo of the current kinase inhibitors as well as knowledge about kinase structure and binding modes. Besides describing the potentials of protein kinase inhibitors as drugs, this review also focus on their limitations, particularly on how to circumvent emerging resistance against kinase inhibitors in oncological indications.
引用
收藏
页码:2675 / 2700
页数:26
相关论文
共 296 条
  • [11] Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
    Ansari, Jawaher
    Hussain, Syed A.
    Ansari, Asif
    Glaholm, John
    [J]. BIOLOGICS-TARGETS & THERAPY, 2013, 7 : 39 - 46
  • [12] Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
    Apperley, Jane F.
    [J]. LANCET ONCOLOGY, 2007, 8 (11) : 1018 - 1029
  • [13] Activation of tyrosine kinases by mutation of the gatekeeper threonine
    Azam, Mohammad
    Seeliger, Markus A.
    Gray, Nathanael S.
    Kuriyan, John
    Daley, George Q.
    [J]. NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2008, 15 (10) : 1109 - 1118
  • [14] A screen to identify drug resistant variants to target-directed anti-cancer agents
    Mohammad Azam
    Tal Raz
    Valentina Nardi
    Sarah L. Opitz
    George Q. Daley
    [J]. Biological Procedures Online, 2003, 5 (1) : 204 - 210
  • [15] Dabrafenib: First Global Approval
    Ballantyne, Anita D.
    Garnock-Jones, Karly P.
    [J]. DRUGS, 2013, 73 (12) : 1367 - 1376
  • [16] Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
    Bantscheff, Marcus
    Eberhard, Dirk
    Abraham, Yann
    Bastuck, Sonja
    Boesche, Markus
    Hobson, Scott
    Mathieson, Toby
    Perrin, Jessica
    Raida, Manfred
    Rau, Christina
    Reader, Valerie
    Sweetman, Gavain
    Bauer, Andreas
    Bouwmeester, Tewis
    Hopf, Carsten
    Kruse, Ulrich
    Neubauer, Gitte
    Ramsden, Nigel
    Rick, Jens
    Kuster, Bernhard
    Drewes, Gerard
    [J]. NATURE BIOTECHNOLOGY, 2007, 25 (09) : 1035 - 1044
  • [17] Mutational analysis of the tyrosine kinome in colorectal cancers
    Bardelli, A
    Parsons, DW
    Silliman, N
    Ptak, J
    Szabo, S
    Saha, S
    Markowitz, S
    Willson, JKV
    Parmigiani, G
    Kinzler, KW
    Vogelstein, B
    Velculescu, VE
    [J]. SCIENCE, 2003, 300 (5621) : 949 - 949
  • [18] Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
    Barker, AJ
    Gibson, KH
    Grundy, W
    Godfrey, AA
    Barlow, JJ
    Healy, MP
    Woodburn, JR
    Ashton, SE
    Curry, BJ
    Scarlett, L
    Henthorn, L
    Richards, L
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) : 1911 - 1914
  • [19] Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors
    Barnett, SF
    Defeo-Jones, D
    Fu, S
    Hancock, PJ
    Haskell, KM
    Jones, RE
    Kahana, JA
    Kral, AM
    Leander, K
    Lee, LL
    Malinowski, J
    McAvoy, EM
    Nahas, DD
    Robinson, RG
    Huber, HE
    [J]. BIOCHEMICAL JOURNAL, 2005, 385 : 399 - 408
  • [20] The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
    Barretina, Jordi
    Caponigro, Giordano
    Stransky, Nicolas
    Venkatesan, Kavitha
    Margolin, Adam A.
    Kim, Sungjoon
    Wilson, Christopher J.
    Lehar, Joseph
    Kryukov, Gregory V.
    Sonkin, Dmitriy
    Reddy, Anupama
    Liu, Manway
    Murray, Lauren
    Berger, Michael F.
    Monahan, John E.
    Morais, Paula
    Meltzer, Jodi
    Korejwa, Adam
    Jane-Valbuena, Judit
    Mapa, Felipa A.
    Thibault, Joseph
    Bric-Furlong, Eva
    Raman, Pichai
    Shipway, Aaron
    Engels, Ingo H.
    Cheng, Jill
    Yu, Guoying K.
    Yu, Jianjun
    Aspesi, Peter, Jr.
    de Silva, Melanie
    Jagtap, Kalpana
    Jones, Michael D.
    Wang, Li
    Hatton, Charles
    Palescandolo, Emanuele
    Gupta, Supriya
    Mahan, Scott
    Sougnez, Carrie
    Onofrio, Robert C.
    Liefeld, Ted
    MacConaill, Laura
    Winckler, Wendy
    Reich, Michael
    Li, Nanxin
    Mesirov, Jill P.
    Gabriel, Stacey B.
    Getz, Gad
    Ardlie, Kristin
    Chan, Vivien
    Myer, Vic E.
    [J]. NATURE, 2012, 483 (7391) : 603 - 607